Jiangling Benda Pharmaceutical: GMP certified

China’s Benda Pharmaceutical, Inc says its subsidiary, Jiangling Benda Pharmaceutical Co., Ltd., has received the Good Manufacturing Practice (GMP) certificate by the Chinese State Food and Drug Administration (SFDA) authorizing the production of Ribavrin at its Jiangling Plant.

Jiangling Benda plans to produce four types of Active Pharmaceutical Ingredients (APIs), including Ribavrin, Asarin, Levofloxacin Mesylate and Ribose.

The production of the APIs, with the exception of Ribose, requires GMP certification.

The Jiangling plant was closed for renovation in July 2004 to comply with GMP standards and was reopened in August 2007 for the production of Ribose.

It currently has all of the production equipment in place, and the new facilities have been installed and tested for Ribavrin and Ribose.